Ameritas Investment Partners’s Cue Biopharma CUE Stock Holding History

Ameritas Investment Partners’s Portfolio CUE Stock Details CUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-95	Closed	-$5.39K	–	3152
2024 Q1	$5.39K	Hold	95	–	–	﹤0.01%	2939
2023 Q4	$7.54K	Hold	95	–	–	﹤0.01%	2910
2023 Q3	$6.56K	Hold	95	–	–	﹤0.01%	2939
2023 Q2	$10.4K	Buy	+95	New	+$11.2K	﹤0.01%	2901
2022 Q2	–	Sell	-82	Closed	-$12K	–	3103
2022 Q1	$12K	Hold	82	–	–	﹤0.01%	2731
2021 Q4	$28K	Hold	82	–	–	﹤0.01%	2475
2021 Q3	$36K	Hold	82	–	–	﹤0.01%	2359
2021 Q2	$29K	Hold	82	–	–	﹤0.01%	2520
2021 Q1	$30K	Hold	82	–	–	﹤0.01%	2375
2020 Q4	$31K	Hold	82	–	–	﹤0.01%	2247
2020 Q3	$37K	Hold	82	–	–	﹤0.01%	2023
2020 Q2	$60K	Buy	82 +29	+55%	+$21K	﹤0.01%	1721
2020 Q1	$22K	Hold	53	–	–	﹤0.01%	2119
2019 Q4	$25K	Hold	53	–	–	﹤0.01%	2297
2019 Q3	$13K	Hold	53	–	–	﹤0.01%	2608
2019 Q2	$14K	Hold	53	–	–	﹤0.01%	2638
2019 Q1	$12K	Hold	53	–	–	﹤0.01%	2625
2018 Q4	$7K	Hold	53	–	–	﹤0.01%	2772
2018 Q3	$14K	Hold	53	–	–	﹤0.01%	2685
2018 Q2	$19K	Buy	53 +28	+112%	+$11.1K	﹤0.01%	2535
2018 Q1	$11K	Buy	+25	New	+$11.4K	﹤0.01%	2684

Other funds holding CUE

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

SPC

Slate Path Capital New York $6.73B AUM 95.97% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

RSWM

Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

GLA

Good Life Advisors Reading, Pennsylvania $1.6B AUM 15.83% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Ameritas Investment Partners's CUE Position: Q2 2024 in Review

Ameritas Investment Partners sold out of Cue Biopharma (CUE) in Q2 2024, closing a stake of 95 shares — an estimated $5.39K sold.

Ameritas Investment Partners first reported a position in CUE in Q1 2018 and held it in 21 quarters. The position peaked at $60K in Q2 2020. 75 funds tracked by Wall St. Rank hold CUE as of Q2 2024.

Ameritas Investment Partners reported no remaining Cue Biopharma position as of Q2 2024 after selling out during the quarter.
Ameritas Investment Partners sold 95 Cue Biopharma shares in Q2 2024, an estimated $5.39K.
Ameritas Investment Partners first reported a position in Cue Biopharma in Q1 2018 and held it in 21 quarters.
Ameritas Investment Partners's Cue Biopharma position peaked at $60K in Q2 2020.
75 funds tracked by Wall St. Rank held Cue Biopharma as of Q2 2024.

Based on Ameritas Investment Partners's 13F filing for Q2 2024, filed 13 Aug 2024.